Search Results - anti-cancer

41 Results

Sort By:

Structure of a SuperSelective primer for the detection and quantitation of rare mutant sequences in the presence of 1,000,000 wild-type sequences; and a demonstration that the number of amplification cycles required to generate a signal above background is inversely linearly proportional to the logarithm of the number of mutant molecules in the original...

Published: 10/9/2024 | Inventor(s): Salvatore Marras, Diana Vargas-Gold, Sanjay Tyagi, Fred Kramer

Keywords(s): Anti-cancer, Sensors & Probes

Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Research Tools, Technology Classifications > Diagnostics

CAR-NK based combinatorial treatment for drug-resistant tumors

Incucyte Killing Assay Images with AnnexinV cell death signal in MKI-Resistant HCC (Top panel). Chromium-51 release assays comparing GRP78 CAR-NK Killing to Naïve NK killing of various MKI-resistant tumor cell lines (bottom panels). Values shown are Means ± SEM. Significant p values indicated in red. Invention Summary: CAR-NK...

Published: 8/19/2024 | Inventor(s): Dongfang Liu, Youssef Sabha, Chih-Hsiung Chen

Keywords(s): Anti-cancer

Category(s): Technology Classifications > Cell Therapy, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics

A novel inhibitory mimetic peptide slows down tumor development

Inhibitory peptide increases caspase3 activity (A) by blocking GC1/Trx1 complex thereby limiting cell proliferation by inducing cell death (B). Invention Summary: Soluble guanylyl cyclase (GC1) and thioredoxin 1 (Trx1), when physically interacting and attaching to each other, they acquire the ability to induce changes in other target...

Published: 7/22/2024 | Inventor(s): Annie Beuve

Keywords(s): Anti-cancer

Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer

Off-the-Shelf CAR-Macrophages for Solid Tumors

Invention Summary: Chimeric Antigen Receptor (CAR) therapy requires isolation of the respective immune cells from the patient’s blood, genetic manipulation, and infusion of the modified cells back into the patient’s body. This makes it personalized and effective but expensive. The CAR-T (modified T cells) therapy has shown...

Published: 1/11/2024 | Inventor(s): Pingping Hou

Keywords(s): Anti-cancer

Category(s): Technology Classifications > Cell Therapy, Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences

PIM-Targeted PROTACs

Abstract: Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers – including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical...

Published: 4/8/2024 | Inventor(s): John Brognard, Rolf Swenson, Pedro Torres-Ayuso, Venkatareddy Sabbasani, Dawid Mehlich, Noel Warfel

Keywords(s): anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

DEVELOPMENT OF SPECIFIC CRK-LIKE ADAPTOR PROTEIN INHIBITORS FOR CANCER THERAPY

NC5 inhibits tumor growth and prolongs survival in vivo. NC5 treatment inhibits TNBC tumor growth and prolongs mice survival in xenograft and PDX mouse models. (A) Survival of mice bearing MDA-MB-231-Luc orthotopic xenograft tumors following treatment with vehicle (black line), Gleevec (blue line), or NC5 (red line). (B) Survival of mice bearing PDX...

Published: 10/29/2024 | Inventor(s): Dongfang Liu, Xuening Wang, Jacques Roberge

Keywords(s): Anti-cancer, Proteins

Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer

Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers

This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express...

Published: 10/28/2024 | Inventor(s): Min Shen, Ke Kong, Toble Lee, Samarjit Patnaik, Olivia Lee, Jonathan Shrimp, Mindy Davis, Juan Marugan, Wei Zhao, Matthew Hall

Keywords(s): Agents, Alcohol, anti-cancer, Class, compounds, HETEROCYCLIC, SULT1A1-dependent, VCXXXX, WKXXXX, XCXXXX, XEXXXX

Category(s): Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology

Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders

The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may...

Published: 10/28/2024 | Inventor(s): Yihong Ye, William Trenkle, Adrian Wiestner

Keywords(s): anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

Method for Generating Memory T-cells In Vitro and Their Use in Immunotherapy

Invention Summary: Dendritic cell-based immunotherapies have been tested for the treatment of cancer patients with limited success. The limited success is probably due to the ineffective activation of specific T-cells by injected dendritic cells. In vitro generation of memory T-cells that can respond to cancer cells could circumvent ineffective T-cell...

Published: 11/3/2022 | Inventor(s): Shigeko Yamashiro (Matsumura), Fumio Matsumura, Aya Matsumura

Keywords(s): Anti-cancer, Immunoassay

Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Research Tools, Technology Classifications > Therapeutics

SAHMI: Microbiome-based screening method for cancer and other diseases

Screening methodology and principle data identifying differences in microbiome diversity from disease state in pancreatic cancer Invention Summary: The microbiome plays an essential role in the prognosis and progression of disease and health, as seen in cancers like pancreatic cancer. Pancreatic cancer is rising in majority of cancer...

Published: 8/8/2022 | Inventor(s): Subhajyoti De, Bassel Ghaddar

Keywords(s): Anti-cancer, Bioinformatics, Biomarkers, Cancer biomarkers

Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Diagnostics, Technology Classifications > Cancer

1 2 3 4 5